MetLife's 2023 Sustainability Report describes progress on our sustainability strategy and commitments, which includes managing business responsibly and creating value for our colleagues, our communities, our customers and our shareholders.
MetLife's 2023 Sustainability Report describes progress on our sustainability strategy and commitments, which includes managing business responsibly and creating value for our colleagues, our communities, our customers and our shareholders.
GEOMETRY-mono1[2]研究中卡马替尼单药治疗高水平MET扩增(GCN ≥10)的肺癌患者,初治和经治患者ORR分别为40%和29%。2023年,Cell Report Medicine期刊发表了VISION研究中原发扩增队列B的详细数据[18],共纳入24例MET扩增(液体活检LBx ...
In 2023, MetLife Foundation launched a new initiative to address the growing income and wealth divide in the U.S. The two-year, $10.5 million pledge supports nonprofit organizations and leaders proximate to the issues who are on the front lines supporting people with low income in communities ...
•Net income of $1.2 billion, or $1.78 per share, compared to net income of $574 million, or $0.77 per share, in the fourth quarter of 2023. •Adjusted earnings of $1.5 billion, or $2.09 per share, compared to adjusted earnings of $1.4 billion, or $1.83 per share, in the four...
2023年,Cell Report Medicine期刊发表了VISION研究中原发扩增队列B的详细数据[20],共纳入24例MET扩增(液体活检LBx GCN ≥2.5)NSCLC患者,其中初治患者获益最为显著。初治患者特泊替尼治疗的ORR为71.4%,经治患者的ORR为29.4%。这些数据提示MET抑制剂...
See our 2023 Report Sustainability Resource Center Previous 1 / 4 Next Corporate Governance Effective leadership, policies and practices underpin MetLife's ability to fulfill our purpose—Always with you, building a more confident future—and deliver on our promise of customer and employee care. ...
See our 2023 Report Sustainability Resource Center Previous 1 / 4 Next Corporate Governance Effective leadership, policies and practices underpin MetLife's ability to fulfill our purpose—Always with you, building a more confident future—and deliver on our promise of customer and employee care. ...
entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content ...
万幸的是患者的肿瘤发现的比较早,所以手术之后也没有使用靶向药,当然用药的话也只能选择MET基因的靶向药,KRAS基因是没有对应的靶向药的。2023年10月,患者返回医院检查提示肿瘤标志物一切正常,患者恢复良好无复发迹象。 病理学诊断为两种原发性肺癌 二、早发现早治疗 ...